Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Caelum Biosciences
Bordentown, New Jersey, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
CAEL-101 demonstrated improved organ function, including cardiac and renal function, in 27 patients with relapsed and refractory AL amyloidosis who had not previously had an organ response to standard of care therapy in a Phase 1a/1b study. The drug is currently in Phase 3 clinical trials.
- Therapeutic areas
- Hematology
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Partnerships
Alexion Pharmaceuticals (now part of AstraZeneca)
Beyond the preview
Go deeper on Caelum Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Caelum Biosciences.